Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. by Lee, Shing Fung & Luque-Fernandez, Miguel Angel
 1Lee SF, Luque-Fernandez MA. BMJ Open 2017;7:e017904. doi:10.1136/bmjopen-2017-017904
Open Access 
AbstrAct
Objectives The clinical course and prognosis of 
follicular lymphoma (FL) are diverse and associated with 
the patient’s immune response. We investigated the 
lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-
lymphocyte ratio (NLR) as prognostic factors in patients 
with FL, including those receiving radiotherapy.
Design A retrospective cohort study.
setting Regional cancer centre in Hong Kong.
Participants 88 patients with histologically proven FL 
diagnosed between 2000 and 2014.
Materials and methods The best LMR and NLR cut-
off values were determined using cross-validated areas 
under the receiver operating characteristic curves. The 
extent to which progression-free survival (PFS) and overall 
survival differed by NLR and LMR cut-off values was 
assessed using Kaplan-Meier analysis and log-rank tests. 
A Cox proportional hazards model was fitted to adjust for 
confounders.
results The best cut-off values for LMR and NLR were 
3.20 and 2.18, respectively. The 5-year PFS was 73.6%. 
After multivariate adjustment, high LMR (>3.20) at 
diagnosis was associated with superior PFS, with a HR of 
0.31 (95% CI 0.13 to 0.71), whereas high NLR at relapse 
was associated with poorer postprogression survival (HR 
1.24, 95% CI 1.04 to 1.49).
conclusions Baseline LMR and NLR at relapse were 
shown to be independent prognostic factors in FL. LMR 
and NLR are cheap and widely available biomarkers 
that could be used in combination with the Follicular 
Lymphoma International Prognostic Index by clinicians to 
better predict prognosis.
IntrODuctIOn
Follicular lymphoma (FL) accounts for 
approximately 20% of all incident lymphoma 
cases, making it the most common indolent 
non-Hodgkin’s lymphoma (NHL). The clin-
ical course and prognosis of FL are diverse.1–6 
Clinical and laboratory parameters assist 
in predicting prognosis, allow for tailoring 
appropriate therapies and aid in selecting 
patients for appropriate clinical trials. The 
commonly used criteria include the Groupe 
d’Etude des Lymphomes Folliculaires 
criteria,7 Follicular Lymphoma Interna-
tional Prognostic Index (FLIPI)2 and Follic-
ular Lymphoma International Prognostic 
Index 2 (FLIPI2).8 FLIPI is a clinical prog-
nostic score and classifies patients into risk 
categories: low, intermediate and high risk. It 
does not include parameters associated with 
tumour microenvironment or host antitu-
mour immune response.
About 20% of patients with FL do not 
respond to or experience progression within 
2 years of treatment; early relapse mani-
fests in a subgroup of patients who are at a 
substantially greater risk of death, and their 
median overall survival (OS) is only 5 years.9 
These cases of high-risk FL may have a distinct 
biology, but it is not easily identified at diag-
nosis; even patients with high-risk disease 
defined by the commonly employed FLIPI2 
could have prolonged survival with modern 
therapy. A biological rationale to account for 
this heterogeneity in patient outcomes would 
provide insights that may influence disease 
monitoring and treatment strategy.
Advances in gene expression profiling 
allow us to elucidate the role of stromal, 
non-malignant cells in the pathogenesis 
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Research
strengths and limitations of this study
 ► We obtained strong evidence in support of 
neutrophil-to-lymphocyte ratio  and lymphocyte-to-
monocyte ratio  as prognostic factors that possess 
practical clinical utility and significance in follicular 
lymphoma.
 ► Sensitivity analysis was performed to determine 
the robustness of the main findings in different 
scenarios.
 ► Association between cell count ratios and systemic 
treatment choices, duration and number of cycles, 
and salvage treatment on progression were not 
analysed because of a limited sample size for 
subgroup analysis.
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Figure 1 Kaplan-Meier curves. Kaplan-Meier estimate for (A) progression-free survival (PFS) and (B) overall survival (OS) of the 
whole study cohort (n=88).
and progression of lymphoma. Immune response-1 and 
immune response-2 are two types of immune responses.10 
Dave et al discovered that most of the component genes 
in prognostically unfavourable immune response-2 signa-
tures are expressed more strongly in the non-malignant 
component of tumours.10 Many genes in the immune 
response-2 signature are highly expressed by peripheral 
blood monocytes. Furthermore, monocyte chemoattrac-
tant protein, a potent chemotactic factor for monocytes, 
and its receptor CC chemokine receptor 2 are shown to 
play roles in modulating inflammatory responses, tumour 
proliferation, angiogenesis and metastasis.11 12 Their 
levels of expression are correlated with cancer prognosis. 
In addition, myeloid-derived suppressor cells are reported 
to have immune-suppressive functions.13–15 Increasing 
numbers of monocytes, macrophages or their precursors 
have been detected in lymphomatous nodes.13 16 Recent 
studies have indicated that the peripheral blood lympho-
cyte-to-monocyte ratio (LMR) at diagnosis can predict 
long-term outcome in patients with diffuse large B-cell 
lymphoma,17 FL,18 19 and Hodgkin lymphoma (HL).20–22 
This evidence indicates that monocytes are an important 
component of the tumour microenvironment.
On the other hand, absolute neutrophil count, a 
surrogate marker of inflammation produced by the 
tumour,23–26 is used in the form of peripheral blood 
neutrophil-to-lymphocyte ratio (NLR) at diagnosis to 
predict survival in diffuse large B-cell lymphoma17 27 and 
HL.28 The rationale behind using these cell count ratios 
is to consider the interaction among components of host 
immunity represented by lymphocytes, inflammation 
produced by the tumour and the tumour microenviron-
ment. However, studies on FL mainly focus on patients 
who were treated with rituximab-containing chemo-
therapy, with little emphasis on those who underwent 
radiotherapy (RT) as a component of or as a primary 
treatment. Moreover, the prognostic role of NLR in FL in 
terms of survival outcomes has not been studied. There-
fore, we aimed to investigate the extent to which NLR at 
diagnosis predicts survival outcomes in patients with FL, 
including those who were treated with RT. We also evalu-
ated whether NLR can be used in combination with FLIPI 
to improve prognosis prediction.
MAterIAls AnD MethODs
study design, setting and participants
We performed a longitudinal study using retrospective 
information from electronic medical records of patients 
with incident FL treated in Tuen Mun Hospital, Hong 
Kong. All FL incident cases from 2000 to 2014 were iden-
tified (n=88). We restricted the analysis to patients with 
complete laboratory, pathology and radiological data in 
the medical records (online supplementary figure S1). 
The sociodemographic information of the excluded 
patients was not different from that of the included 
patients in the final sample. Patients were followed up for 
a median of 5.88 (range: 0.49–16.45) years. The periph-
eral blood count results were obtained from a standard 
automated complete blood count machine. This study was 
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Table 1 Descriptive summary statistics for the best cut-offs of LMR and NLR according to patient clinical characteristics, 
n=88
Characteristics
All patients
(n=88)
LMR >3.20
(n=49)
LMR ≤3.20
(n=39)
NLR >2.18
(n=57)
NLR ≤2.18
(n=31)
Age, years
Median (range) 54 (22–87) 53 (22–87) 54 (31–78) 55 (31–87) 52 (22–77)
  >60, n (%) 29 (33.0) 16 (32.7) 13 (33.3) 24 (42.1) 5 (16.1)
  ≤60, n (%) 59 (67.0) 33 (67.4) 26 (66.7) 33 (57.9) 26 (83.9)
Sex, n (%)
  Male 47 (53.4) 29 (59.2) 18 (46.2) 27 (47.4) 20 (64.5)
  Female 41 (46.6) 20 (40.8) 21 (53.9) 30 (52.6) 11 (35.5)
FLIPI, n (%)
  Low risk (scores 0–1) 16 (18.2) 9 (18.4) 7 (18.0) 6 (10.5) 10 (32.3)
  Intermediate risk (score 2) 19 (21.6) 13 (26.5) 6 (15.4) 10 (17.5) 9 (29.0)
  High risk (scores 3–5) 53 (60.2) 27 (55.1) 26 (66.7) 41 (71.9) 12 (38.7)
  ANC (109/L), median 
(range)
4.2 (1.9–10.7) 3.7 (1.9–7.9) 4.6 (2.1–10.7) 4.6 (2.1–10.7) 3.5 (1.9–7.9)
  ALC (109/L), median 
(range)
1.6 (0.6–11.3) 1.9 (0.7–11.3) 1.1 (0.6–3.1) 1.2 (0.6–3.1) 2.1 (1.4–11.3)
  AMC (109/L), median 
(range)
0.4 (0.1–1.2) 0.4 (0.1–0.9) 0.5 (0.2–1.2) 0.4 (0.1–1.2) 0.4 (0.2–1.1)
  NLR, median (range) 2.76 (0.59–9.91) 2.15 (0.59–8.50) 3.83 (1.81–9.91) 3.50 (2.20–9.91) 1.73 (0.59–2.18)
  LMR, median (range) 3.80 (0.55–22.60) 5.00 (3.43–22.60) 2.33 (0.55–3.20) 3.00 (0.55–8.00) 5.33 (2.82–22.60)
  LDH >220 IU/L, n (%) 70 (80.5) 39 (81.3) 31 (79.5) 47 (82.5) 23 (76.7)
Stage, n (%)
  I/II 24 (27.3) 14 (28.6) 10 (25.6) 11 (19.3) 13 (41.9)
  III/IV 64 (72.7) 35 (71.4) 29 (74.4) 46 (80.7) 18 (58.1)
  Hb <12 g/dL, n (%) 23 (26.1) 14 (28.6) 9 (23.1) 15 (26.3) 8 (25.8)
  Number of nodal sites >4, 
n (%)
50 (56.8) 24 (49.0) 26 (66.7) 37 (64.9) 13 (41.9)
  Use of rituximab, n (%) 38 (43.2) 19 (38.8) 19 (48.7) 27 (47.4) 11 (35.5)
Treatment, n (%)
  Chemotherapy plus RT 14 (15.9) 9 (10.2) 5 (5.7) 8 (9.1) 6 (6.8)
  Chemotherapy alone 54 (61.4) 26 (29.5) 28 (31.8) 40 (45.5) 14 (15.9)
  RT alone 14 (15.9) 9 (10.2) 5 (5.7) 6 (6.8) 8 (9.1)
ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; FLIPI, Follicular Lymphoma International 
Prognostic Index; Hb, haemoglobin; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; 
RT, radiotherapy.
approved by the Clinical and Research Ethics Committee 
of the Tuen Mun Hospital, Tuen Mun, Hong Kong 
(NTWC/CREC/16107). The research was conducted in 
accordance with the 1964 Declaration of Helsinki and its 
later amendments.
Data and variables
OS and progression-free survival (PFS) were the main 
outcomes of the study. These outcomes were defined and 
measured as per criteria from the International Harmoni-
zation Project.29 OS was defined as the time from diagnosis 
until death as a result of any cause or the last follow-up visit 
for censored patients. PFS was defined as the time from 
diagnosis until lymphoma progression (first date of docu-
mentation of a new lesion or enlargement of a previous 
lesion) or death as a result of any cause or last follow-up 
visit for censored patients. Postprogression survival (PPS) 
was defined as the time from progression or relapse to the 
date of death as a result of any cause or last follow-up visit for 
censored patients. For the survival endpoints, patients were 
censored at their last follow-up visit. Patients’ demographics 
and disease characteristics were collected. The FLIPI score 
was then calculated using those factors (nodal sites, age, 
serum lactate dehydrogenase, stage and haemoglobin) (see 
online supplementary table S1).2 Chemotherapy involved 
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Table 2 HRs of PFS events, n=88
Cases/1000 person-years Rate (per 1000 person-years) HR 95% CI p Value
LMR
  >3.20 11 34.66 0.34 0.16 to 0.74 0.004
  ≤3.20 16 101.28 1
NLR
  >2.18 18 67.37 1.56 0.70 to 3.47 0.273
  ≤2.18 9 43.23 1
FLIPI
  High risk 19 82.30 2.52 1.10 to 5.75 0.023
  Low/intermediate risk 8 32.72 1
Sex
  Male 15 58.96 1.09 0.51 to 2.32 0.831
  Female 12 54.29 1
Rituximab
  Yes 4 22.02 0.28 0.10 to 0.81 0.012
  No 23 78.31 1
Year of diagnosis
  2010–2014 1 8.71 0.10 0.01 to 0.75 0.006
  2006–2010 5 43.05 0.50 0.19 to 1.33 0.157
  2000–2005 21 85.91 1
FLIPI, Follicular Lymphoma International Prognostic Index; LMR, lymphocyte-to-monocyte ratio; NLR neutrophil-to-lymphocyte ratio; PFS, 
progression-free survival.
cyclophosphamide, vincristine and prednisolone or cyclo-
phosphamide, doxorubicin, vincristine and prednisolone 
(CHOP) or CHOP-like regimens.
statistical methods
We initially described the cohort of patients using ranges 
(minimum, maximum), means and SD for continuous 
variables and proportions for categorical variables. 
To evaluate LMR and NLR performance in predicting 
mortality, we fitted two logistic models with cancer-re-
lated death as the outcome and LMR and NLR as contin-
uous independent predictors. Data-adaptive methods 
based on Bayesian and Akaike information criteria were 
used to determine the impact of any associated factors 
and to identify the best fitting model. Subsequently, we 
computed marginal probabilities for the outcome based 
on two different weighted logistic models, with time 
and NLR as independent predictors for the first model 
and time and LMR for the second model. Weights were 
accounted for the inverse probability of censoring.30 
Then we derived cross-validated areas under the curve 
(AUC)31; afterwards we chose the best cut-off values based 
on the cross-validated sensitivity, specificity and the Youd-
en’s indices (sensitivity+specificity−1). Respective LMR 
and NLR cut-off values were determined at a point with 
the maximum Youden’s index on the receiver operating 
characteristic (ROC) curve.32 33 To evaluate the extent to 
which OS and PFS differ by LMR and NLR cut-off values, 
we used incidence, rate ratios, Kaplan-Meier analysis and 
log-rank tests34 35 for statistical inference. We also used 
semiparametric Cox proportional hazards models to 
evaluate OS and PFS for the computed LMR and NLR 
cut-off values adjusted for FLIPI, use of rituximab and 
sex.36 37 Finally, we developed a sensitivity analysis to 
evaluate the robustness of our findings in the multivar-
iate analysis including different model specifications to 
account for non-linearities and the interaction between 
rituximab and LMR/NLR levels. The proportional 
hazard assumption for multivariate-adjusted Cox models 
was also assessed based on the analysis of the Schoenfeld 
residuals. We used Stata V.14.2 (StataCorp) for the statis-
tical analysis.
results
Description of the cohort
The median age at diagnosis of the patients included in 
the study was 54 years (range: 22–87 years). Among them, 
18 died during the follow-up period. Thirteen patients 
died due to the lymphoma. Five deaths were non-lym-
phoma related: one patient developed prostate cancer 
and died of pneumonia, another three died of commu-
nity-acquired pneumonia and one died of acute coronary 
syndrome and renal failure. The estimated 5-year PFS 
and OS were 73.6% and 85.6%, respectively (figure 1). 
At diagnosis, 18.2%, 21.6% and 60.2% were classified as 
being at low, intermediate and high risk according to the 
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Figure 2 Adjusted progression-free survival (PFS). Estimate of (A) high and low lymphocyte-to-monocyte ratio (LMR) at 
diagnosis and (B) high and low neutrophil-to-lymphocyte ratio (NLR) at diagnosis (n=88).
Table 3 Multivariate analyses of PFS with LMR and NLR at diagnosis, n=88
Adjusted HR* 95% CI p Value
LMR: >3.20 vs ≤3.20 (reference) 0.31 0.13 to 0.71 0.006
FLIPI: high risk vs low/intermediate risk (reference) 2.17 0.92 to 5.10 0.075
Sex: male vs female (reference) 1.50 0.67 to 3.34 0.321
Rituximab use: yes vs no (reference) 0.16 0.05 to 0.48 0.001
Adjusted HR* 95% CI p Value
NLR: >2.18 vs ≤2.18 (reference) 1.33 0.57 to 3.10 0.511
FLIPI: high risk vs low/intermediate risk (reference) 2.47 1.03 to 5.89 0.042
Sex: male vs female (reference) 1.15 0.53 to 2.48 0.721
Rituximab use: yes vs no (reference) 0.19 0.07 to 0.57 0.003
*Adjusted for all other covariates in the table.
FLIPI, Follicular Lymphoma International Prognostic Index; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PFS, 
progression-free survival.
FLIPI score. Table 1 shows the descriptive summary statis-
tics of patients included in the study.
Only 18 patients underwent RT as a definitive treat-
ment for limited stages I and II. Involved-field irradia-
tion, in which the RT fields were limited to the involved 
nodal region, was mostly administered with two parallel 
opposed fields; the median radiation dose was 40 Gy 
(range: 30–54 Gy). Ten other patients with stage III or 
IV disease received RT during their disease course, as 
part of palliation or as consolidation therapy to sites 
demonstrating an inadequate response to systemic treat-
ment. High-grade transformation occurred in 6 out of 27 
patients with relapse. Peripheral blood counts were avail-
able at the time of the relapse.
Progression-free survival
The AUCs of LMR and NLR were 0.90 (95% CI 
0.84 to 0.97) and 0.87 (95% CI 0.77 to 0.96), respectively, 
and they did not differ in terms of predictive performance 
for PFS (test equality of ROC areas, p value 0.470). An 
LMR cut-off value of 3.20 (positive predictive value 22.4% 
and negative predictive value 82.1%; sensitivity 61.1% 
and specificity 45.7%) and NLR cut-off value of 2.18 
(positive predictive value 21.1% and negative predictive 
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value 80.6%; sensitivity 66.7% and specificity 35.7%) 
showed the greatest Youden’s index, corresponding to 
maximum joint sensitivity and specificity on the ROC 
curve (online supplementary table S2).
nlr and lMr mortality predictive performance
The median NLR and LMR at diagnosis were 2.77 (range: 
0.59–9.91) and 3.80 (range: 0.55–22.60), respectively. 
The median NLR and LMR at relapse were 2.67 (range: 
0.95–17.25) and 3.33 (range: 0.48–8.5), respectively.
NLR at relapse was associated with PPS as a continuous 
variable (HR 1.24, 95% CI 1.04 to 1.49). In the univar-
iate analysis presented in table 2, high LMR (>3.20) had 
a superior PFS with a HR of 0.34 (95% CI 0.16 to 0.74). 
Patients with a high FLIPI score had a 2.5 times greater risk 
of death or relapse than patients with a lower score (HR 
2.52, 95% CI 1.10 to 5.75). However, patients treated with 
rituximab had a 72% lower risk of death or relapse (HR 
0.28, 95% CI 0.10 to 0.81). We found evidence of a linear 
association between PFS and the calendar period (p value 
of trend=0.003). Compared with the period 2000–2005, 
those patients diagnosed during 2010–2014 had a 90% 
lower risk of death or relapse (HR 0.10, 95% CI 0.01 to 
0.75). Furthermore, there was no evidence of differences 
in PFS by sex (male vs female, HR 1.09, 95% CI 0.51 to 
2.32). LMR at relapse showed a weak association with PPS 
(HR 1.06, 95% CI 0.77 to 1.45).
In the multivariate analysis, patients with a high LMR 
(>3.20) at diagnosis had a longer PFS, with an adjusted 
HR of 0.31 (95% CI 0.13 to 0.71) (figure 2). However, 
NLR cut-off levels did not show strong evidence of an 
association with PFS (adjusted HR 1.33, 95% CI 0.57 to 
3.10) (table 3).
sensitivity analysis
Sensitivity analysis showed that LMR was consistently asso-
ciated with PFS under different model specifications and 
multivariate adjustments. We evaluated the multivariate 
analyses, and found that the assumption for the propor-
tional hazard was met. However, the strength of the 
evidence for differences in OS by LMR and NLR levels 
was weak.
PFS tended to increase with LMRs above the cut-off 
and low FLIPI scores (HR LMR >3.2 and low FLIPI 0.17, 
95% CI 0.04 to 0.70 vs HR LMR >3.2 and high FLIPI 0.60, 
95% CI 0.24 to 1.50), but evidence of a statistical inter-
action was weak (interaction p value 0.171). There was 
some evidence of a statistical interaction between LMR 
and rituximab (interaction p value 0.024, HR of the inter-
action term 17.1, 95% CI 1.46 to 199.36).
DIscussIOn
To our knowledge, this study is the first to report the clin-
ical and prognostic implications of pretreatment NLR 
in patients with FL. Our findings demonstrated notable 
differences in clinical behaviour and outcome between the 
low and high LMR groups at diagnosis and NLR groups at 
the time of relapse. Previous studies reported that NLR is 
a predictor of mortality in several cancer types, including 
gastric38 39 and colorectal cancer.40 One possible under-
lying mechanism is the inflammatory reaction, which has 
been reported to be involved in tumour growth, invasion, 
metastasis and resistance to treatment.23–26
The factors included in FLIPI2 are primarily related 
to tumour burden (stage, serum lactate dehydrogenase, 
and number of nodal site involvement) and patient char-
acteristics (age and haemoglobin). Cell count ratio at 
diagnosis is a simple tool that assesses the host’s immune 
homoeostasis, inflammatory state23 24 and the tumour 
microenvironment.14 15 We obtained strong evidence in 
support of these prognostic factors possessing practical 
clinical utility and significance. In the present study, LMR 
played a significant role in predicting the PFS and NLR 
in PPS; however, the strength of the evidence for OS was 
weak. This weak evidence may be attributed to the inad-
equate sample size and the few deaths observed, along 
with the interaction with other parameters or unknown 
confounding. Moreover, the availability of salvage treat-
ments on progression makes the difference in OS diffi-
cult to demonstrate.
Cell count or its ratio at diagnosis may be used to decide 
which treatment strategy is most appropriate, including 
watchful waiting, RT or systemic treatment. Previous 
studies showed that lymphocytes have an important role 
in mediating the antitumour effect of rituximab.41–43 For 
those with low LMR, the disease may progress earlier, and 
closer follow-up may be indicated. We separated patients 
into FLIPI-based low/intermediate and high-risk groups 
and then incorporated a biological factor (LMR) into a 
known clinical prognostic factor (FLIPI). Based on the 
findings of our study, future studies should aim to under-
stand the utility of cell count ratios with other established 
prognostic factors in an independent validation cohort 
and to explore the therapeutic strategies based on cell 
count ratio (ie, observation alone vs early initiation of 
treatment), ideally in a prospective manner.
Most studies are subject to a certain degree of misclas-
sification related to measurement error.44 However, our 
study population followed standardised investigation 
procedures; any misclassification is likely to be non-differ-
ential. The incidence and spectrum of NHL cases differ 
between the Chinese and Western populations, and the 
risk of FL is lower in the former group.45–47 However, our 
sample size is comparable to those in other retrospective 
FL studies in Asia, ranging between 40 and 50 patients.45 48 
Both genetic and environmental factors play a part in 
governing the overall incidence, as shown by migration 
studies.46 Our lymphoma treatment regimens were not 
completely uniform in this analysis and involved a modest 
sample size, which may have introduced selection bias. 
We analysed a group of patients receiving definitive RT as 
treatment, with a sample size of only 18. The results did 
not reach statistical significance; a bigger cohort or even 
a dedicated prospective study would be interesting. In 
our data, the complete blood count did not differentiate 
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the subtypes of B and T lymphocytes and monocytes. 
Therefore, information regarding patient outcomes with 
a combination of different subtypes of immune cells was 
not explored in this study. Furthermore, in our study, the 
distribution of blood cells may be different when leuco-
cytosis or leucopenia is present. Moreover, evidence of a 
correlation between age and circulating white cell counts 
has been reported, and a decrease in total lymphocyte 
counts is observed more frequently in the elderly than 
in younger adults.49 Also, the treatments may interact 
with other factors, such as age and performance status. 
There appears to be an interaction between rituximab 
and LMR. However, the 95% CI of the interaction term 
was wide; this reflected the small numbers and data spar-
sity for secondary analysis, and therefore, no conclusive 
evidence can be extrapolated. We did not analyse the 
association between cell count ratios and systemic treat-
ment choices, duration and number of cycles and salvage 
treatment on progression because of the limited sample 
size for the subgroup analysis. Given the unavailability of 
beta-2 microglobulin in most patients, we did not analyse 
FLIPI2.
One merit of our study is the performance of a sensi-
tivity analysis to determine the robustness of the main 
findings in different scenarios. A sensitivity analysis was 
not conducted in numerous studies assessing the relation-
ship between cell count ratio and survival. Furthermore, 
we explored the effect of calendar year of diagnosis to 
account for potential improvement in life expectancy 
over the study period due to changes in the environment 
or technological advancement in general medical care. 
Also, we accounted for the impact of the inclusion of 
rituximab as a therapeutic option since early 2005, which 
is strongly correlated with an improved OS and PFS.
The external validity of this study is limited to a single 
institution. Thus, further evidence for validation of our 
results and multi-institutional studies with larger sample 
sizes are warranted. However, the strength of the evidence 
of our findings is still important given the clinical rele-
vance of LMR and NLR capability to predict prognosis.
cOnclusIOn
In this study, we demonstrated that LMR and NLR may 
provide independent and additional prognostic infor-
mation for risk classification when used along with FLIPI 
in FL. These can be determined using widely available 
complete blood count tests, which can be used as non-in-
vasive and cost-effective alternatives to complement prog-
nosis data for FL. Future prospective studies are necessary 
to validate the results of our study and evaluate the exact 
clinical significance.
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